Accessibility Statement
Beyfortus Accessibility Statement
1. Commitment
Sanofi is committed to providing digital solutions that are accessible to the widest possible audience, regardless of ability, disability, race, cultural background, gender, or technological requirements.
This accessibility statement applies to https://www.beyfortus.com/us and https://www.beyfortus.com/us-es
2. Conformance status
The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. This website is partially conformant with WCAG 2.2 Level AA, due to the limitations described below.
3. Known limitations
Despite our best efforts to ensure the accessibility of this website, there may be some limitations. Below is a description of known limitations and potential solutions. Please contact us if you observe an issue not listed below.
- Images: Some images and icons lack descriptive alternative text.
- ARIA attributes: Certain elements with ARIA roles may have invalid or missing attributes.
- Interactive controls: Some interactive controls are nested, which can affect screen reader navigation
- Color contrast: Some text and link elements do not meet minimum color contrast requirements.
- Touch targets: Touch targets in some areas may be smaller than recommended for easy activation.
- Videos: Some videos do not include transcripts or audio descriptions.
- Keyboard focus: When navigating the site by keyboard, the focus state or highlight is challenging to see, including some buttons that are inside of colored containers in the footer.
- Links readability: Some links are identified only with color.
- Headings: Certain headings may not be presented in a semantic order.
- Downloadable resources: Certain downloadable resources may not be fully optimized for assistive technologies
We intend to address the above issues by Dec 2026.
4. Feedback and contact
Please contact us if you encounter accessibility barriers on this website. If you are unable to access any content or service, we will provide an accessible alternative or offer the content in another form.
5. Preparation of this accessibility statement
This statement was prepared on 17 November 2025.
To evaluate the current level of accessibility, the website was assessed using automated testing in Axe Monitor, based on WCAG 2.2 Level AA, with Google Chrome.
Some manual testing with keyboard was also performed.
Further tests and updates will be carried out by end of Dec 2026.
6. Formal complaints
If you are not satisfied with our response to you, you are entitled to escalate a complaint to the national authority.
To file an Americans with Disabilities (ADA) complaint, submit a report with the US Department of Justice, Civil Rights Division, online or by mail. Learn how to file a complaint on the Civil Rights Division website.
Your child should not take Beyfortus if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in Beyfortus.
Before your child receives Beyfortus, tell your healthcare provider about all of your child’s medical conditions, including if your child:
- has ever had a reaction to Beyfortus.
- has bleeding or bruising problems. If your child has a problem with bleeding or bruises easily, an injection could cause a problem.
Tell your healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received Beyfortus in the same RSV season.
Serious allergic reactions have happened with Beyfortus. Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction:
- swelling of the face, mouth, or tongue
- difficulty swallowing or breathing
- unresponsiveness
- bluish color of skin, lips, or under fingernails
- muscle weakness
- severe rash, hives, or itching
The most common side effects of Beyfortus include rash and pain, swelling, or hardness at the site of your child’s injection. These are not all the possible side effects of Beyfortus. Call your healthcare provider if you have questions about side effects.
Please see full Prescribing Information, including Patient Information, for more details.
Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.
Beyfortus is a prescription medicine used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in:
- Newborns and babies under 1 year of age born during or entering their first RSV season.
- Children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season.
